Filter
750
Filtered Results: 750
Text search:
drug
manufacturing
Featured
Recommendations
59
New Publications
189
Language
Document type
No document type
370
Studies & Reports
148
Guidelines
126
Manuals
38
Strategic & Response Plan
37
Fact sheets
12
Situation Updates
8
Training Material
5
Resource Platforms
3
Infographics
2
Brochures
1
Countries / Regions
India
36
Global
33
Kenya
32
Ghana
20
Nigeria
20
Uganda
19
Ethiopia
18
Western and Central Europe
14
South Africa
14
Sierra Leone
13
Bangladesh
13
Nepal
12
Tanzania
12
Zambia
12
Africa
11
Lesotho
9
Malawi
9
Botswana
9
Ukraine
8
Zimbabwe
8
Liberia
8
South–East Asia Region
7
Namibia
7
Myanmar / Burma
7
Rwanda
6
Philippines
6
Latin America and the Carribbean
6
Eastern Europe
5
Indonesia
5
Eswatini/ Swaziland
4
Tajikistan
3
Thailand
3
Albania
3
Haiti
3
Cambodia
3
West and Central Africa
3
East and Southern Africa
3
Russia
3
Cameroon
2
Laos
2
Senegal
2
Mozambique
2
Asia
2
Germany
2
Western Pacific Region
2
Eastern Europe and Central Asia
2
Moldova
2
Sudan
2
Pakistan
2
Serbia
1
Australia
1
Benin
1
China
1
Syria
1
Burkina Faso
1
Uzbekistan
1
Mongolia
1
Guinea
1
USA
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
Turkmenistan
1
Maldives
1
Mauritius
1
Vietnam
1
Brazil
1
Sri Lanka
1
South Sudan
1
Iraq
1
Solomon Islands
1
Madagascar
1
Authors & Publishers
Publication Years
Category
Countries
305
Clinical Guidelines
62
Public Health
32
Pharmacy & Technologies
30
Key Resources
20
Women & Child Health
13
Capacity Building
5
Toolboxes
Pharmacy
86
AMR
85
COVID-19
54
HIV
48
TB
39
Mental Health
34
NTDs
21
Planetary Health
17
Rapid Response
14
Ebola & Marburg
14
NCDs
14
Health Financing Toolbox
12
Global Health Education
12
Specific Hazards
6
Caregiver
6
Conflict
5
Cholera
4
Natural Hazards
3
Malaria
3
Polio
2
Refugee
1
Disability
1
Zika
1
Every day, fake medicines and medical products are sold at street corners, in open air markets or on unregulated websites in several countries in the African Region. These poor quality, unsafe medicines and pharmaceutical products promote drug resistance and lead to loss of confidence in health prof...
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug...
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...
Am. J. Trop. Med. Hyg., 106 (Suppl 5), 2022, pp. 56–60. Lymphatic filariasis (LF) is a parasitic disease that is a major cause of chronic disability in the developing world. According to the 2021–2030 road map for neglected tropical diseases (NTDs) published by the World Health Organization (WHO...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
Improvements in water sanitation and hygiene (WASH) and wastewater management in all sectors are critical elements of preventing infections and reducing the spread of antimicrobial resistance (AMR) as identified in the Global Action Plan to combat AMR. Yet, at present, WASH and wastewater management...
The Global Programme on Tuberculosis & Lung Health of the World Health Organization (WHO/GTB) is now combining all current recommendations into one overall set of consolidated guidelines on TB. The guidelines contain recommendations pertaining to all areas related to the programmatic management of T...
Drugs and medical supplies are dispensed at the cutting edge level of the interface between the public health system and the people. Availability or lack of it brings either credit or discredit to the public health system. The primary reason for holding stocks of medicines and medical supplies in a ...
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...
The Practical manual on laboratory strengthening, 2022 update provides practical guidance on implementation of WHO recommendations and best practices for TB laboratory strengthening. It is an updated version of the GLI Practical Guide to Laboratory Strengthening published in 2017 and provides the la...
Guidelines for the production of extemporaenous formulations and hospital based sterile preparations
In order to streamline and effectively control compounding of medicinal products in hospitals and pharmacies, these Guidelines for Production of Extemporaneous and Hospital Based Sterile Preparations has been crafted. The purpose of these guidelines therefore is to assist pharmacists in ...
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...
The extensive use of antimicrobials in human and veterinary medicine in recent years has accelerated the emergence and spread of resistant microorganisms. This situation has been worsened by the lack of investment in developing new effective antibiotics. The severity of the consequences is clear to ...
Long-term polio vaccine security – the timely, sustained, and uninterrupted supply of suitable types of affordable, quality-assured polio vaccines – is essential in the global effort to achieve and maintain a polio free world. However, fragmented approaches and short-term planning pose considera...
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...
An Act to repeal the Dangerous Medicines Act of 1973,to ensure the availability of certain drugs for exclusive medical, scientific and related purposes, while preventing their abuse; to prevent the diversion from lawful trade of controlled chemicals, controlled equipment and controlled materials for...
This document summarizes the results of the WHO-commissioned full value proposition for new tuberculosis (TB) vaccines. The assessment was commissioned to provide early evidence for national and global decision-makers involved in TB vaccine development and implementation, who include stakeholders in...
The document provides detailed guidelines for the production, formulation, and implementation of oral rehydration salts (ORS) to combat dehydration caused by diarrhoea, particularly in children. It focuses on the composition, quality standards, and packaging requirements of ORS, aiming to support na...
Ahead of World Malaria Day, the WHO Global Malaria Programme published a new operational strategy outlining its priorities and key activities up to 2030 to help change the trajectory of malaria trends, with a view to achieving the global malaria targets. The strategy outlines 4 strategic objectives ...
